newsfilter
← Latest News
GlobeNewswire·

Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement

HOUSTON, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company")), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the receipt